IDDI Task Force

egg_5712-1.jpg

What is the IDDI?

The Innovative Drug Development Initiative (IDDI) is a transformational activity within the PVRI that facilitates the development of novel treatments for patients with pulmonary hypertension (PH) and right ventricular failure and establishes them into clinical practice. 

All active PVRI members who are interested in contributing to this activity are encouraged to join the Task Force.

Why is this important?

Pulmonary vascular disease is a field of high unmet medical need covering orphan diseases and is the special focus of the PVRI. We provide a platform for academia, the pharmaceutical industry, and drug regulators to openly discuss questions surrounding issues such as the future of clinical trial design, access to care, and improving communications between stakeholders. 

 

We encourage early and continuous dialogue with all stakeholders, including patients, on innovative clinical and regulatory development strategies, with the aim of finding new ways to fight and treat pulmonary vascular disease and pulmonary hypertension as life-threatening conditions.

IDDI’s 5 Year Plan

  • Create and facilitate a platform to allow discussion and harmonisation of ideas between Pharma, Academia and Regulators to build awareness on the disease and explore options to early diagnosis and treatment.
  • Explore innovative and suitable clinical trial designs, endpoints, biomarkers and re-purposing drugs opportunities for different forms of pulmonary hypertension (PH).
  • Leverage deep phenotyping programmes at PH specialised centres to inform and enrich new clinical trial designs based on patient subsets (“Personalised Medicine”).
  • Explore acceleration potential of clinical trials to bring novel orphan drugs as soon as possible to this critically ill group of pulmonary hypertension patients.
  • Include the view of patients, regulators and nurses, and their advocacy groups.

IDDI’s 10 Year Aspirations

  • To be recognised as a centre of excellence for free, in-depth scientific exchange of information and its timely utilisation in the field of pulmonary vascular diseases.
  • Driving the finding of innovative treatments, and potentially a cure for pulmonary hypertension and other PH related rare diseases.
  • Successfully harmonising and developing protocol designs, biomarkers and endpoints to expedite availability of critical new treatments and drugs especially those for treating rare diseases.
  • Providing scientific input to guidelines for the optimal diagnosis and treatment of all forms of pulmonary hypertension.

Output recognised by the field

IDDI Task Force publishes a special collection in Pulmonary Circulation that presents the collaborative outcome of the work of the four IDDI workstreams on clinical trial design, biomarkers, endpoints and repurposing drugs.

 

This task force is lead by Raymond Benza, Mark Toshner, Sylvia Nikkho and Peter Fernandes.

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg